[GENFIT 2021 Annual Report Filing and Corporate Update](index=1&type=section&id=GENFIT%20Announces%20Publication%20of%20the%202021%20Universal%20Registration%20Document%3B%20the%202021%20Annual%20Report%20on%20Form%2020-F%20and%20Availability%20of%20Preparatory%20Documents%20for%20the%20Annual%20Combined%20Shareholders%20Meeting%20on%20May%2025%2C%202022) [Announcement of Financial Report Filing and Shareholders Meeting](index=1&type=section&id=Announcement%20of%20Financial%20Report%20Filing%20and%20Shareholders%20Meeting) GENFIT announced the filing of its 2021 Universal Registration Document and Annual Report on Form 20-F, with preparatory documents for the May 25, 2022, Annual Shareholders Meeting now available - GENFIT filed its 2021 Universal Registration Document with the AMF and its Annual Report on Form 20-F with the SEC on **April 29, 2022**[2](index=2&type=chunk) - The 2021 Universal Registration Document encompasses the annual financial report, management report, corporate governance report, and auditors' reports[4](index=4&type=chunk) - Preparatory documents for the Annual Combined Shareholders Meeting on **May 25, 2022**, are accessible to shareholders via the company's website[5](index=5&type=chunk) [Company Overview and R&D Pipeline](index=1&type=section&id=ABOUT%20GENFIT) GENFIT is a late-stage biopharmaceutical company focused on severe chronic liver diseases, with R&D in cholestatic diseases, ACLF, and NASH diagnostics, featuring a diversified pipeline and key partnerships - GENFIT's R&D focuses on three franchises: cholestatic diseases, Acute on Chronic Liver Failure (ACLF), and NASH diagnostics[8](index=8&type=chunk) Pipeline Overview | Pipeline / Product | Indication | Phase / Status | Key Partner / Agreement | | :--- | :--- | :--- | :--- | | Elafibranor (ELATIVE™) | Primary Biliary Cholangitis (PBC) | Phase 3 | Ipsen (Develop, manufacture, commercialize) | | GNS561 | Cholangiocarcinoma | Development | Genoscience Pharma (Exclusive rights) | | Nitazoxanide | ACLF | Phase 1 | - | | NASHnext® (NIS4®) | At-risk NASH Identification | Commercialization | Labcorp | - In 2021, Ipsen became a major shareholder, holding **8%** of GENFIT's share capital[9](index=9&type=chunk) - Topline data for the Phase 3 trial of elafibranor in PBC is anticipated in **early 2023**, with Phase 1 nitazoxanide data in ACLF expected as early as **Q3 2022**[8](index=8&type=chunk) [Forward-Looking Statements and Risk Factors](index=3&type=section&id=FORWARD%20LOOKING%20STATEMENTS) The press release contains forward-looking statements regarding R&D programs and clinical trial results, subject to risks detailed in public filings with the AMF and SEC - The document contains forward-looking statements concerning R&D programs and clinical trial data readouts, which do not guarantee future performance[10](index=10&type=chunk) - Investors should refer to the company's public filings, including Chapter 2 of the 2021 Universal Registration Document (D.22-0400) and the 2021 Annual Report on Form 20-F, for a comprehensive list of risks and uncertainties[10](index=10&type=chunk)

Corporate Presentation April 2022 Disclaimer & Looking Forward Statement IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED BY THIRD-PARTY CONSULTANTS AND OTHER INDUSTRY SOURCES. WHILE GENFIT BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM WHICH IT HAS B ...

Genfit SA (NASDAQ:GNFT) Q4 2021 Earnings Conference Call April 8, 2022 8:00 AM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - Chief Executive Officer Tom Baetz - Chief Financial Officer Dean Hum - Chief Scientific Officer Carol Addy - Chief Medical Officer Conference Call Participants Thomas Smith - SVB Leerink Arsene Guekam - Kepler Cheuvreux Ed Arce - H.C. Wainwright Operator Good day, and welcome to the Genfit's Full-Year 2021 Financial Results and Corporate Upd ...

| | | Page | | --- | --- | --- | | PART I | | 9 | | Item 1. | Identity of Director, Senior Management and Advisers | 9 | | Item 2. | Offer Statistics and Expected Timetable | 9 | | Item 3. | Key Information | 9 | | Item 4. | Information on the Company | 57 | | Item 5. | Operating and Financial Review and Prospects | 98 | | Item 6. | Directors, Senior Management and Employees | 116 | | Item 7. | Major Shareholders and Related Party Transactions | 138 | | Item 8. | Financial Information | 142 | | Item 9. | Th ...

GENFIT SA (NASDAQ:GNFT) Q2 2020 Results Conference Call September 30, 2020 4:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scientific Officer and COO Conference Call Participants Thomas Smith - SVB Leerink Derek Archila - Stifel Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the GENFIT Half Year 2020 Financial Report and New Corporate Strategy Conference Call. At this time, all participants are in a listen-only mode. A qu ...

June 19, 2020 2020 CORPORATE PRESENTATION 2020 Disclaimer & Forward Looking Statements IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED BY THIRD-PARTY CONSULTANTS AND OTHER INDUSTRY SOURCES. WHILE GENFIT BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission File Number 001-38844 GENFIT S.A. (Exact name of Registrant as specified in its charter and translation of Registrant's name into English) FRANCE FORM 20-F ☐ REGISTRATION ST ...